FEB 0 7 2006 By Docket No. 5808.04

2-18-06

Ifw

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Qaber et al.)	
Application No.: 10/774,043)	
)	Group Art Unit: 1617
Filed: February 5, 2004)	•
)	Examiner: Unknown
For: BETA-SHEET MIMETICS AND)	
METHODS RELATING TO THE USE)	
THEREOF)	

CERTIFICATE OF EXPRESS MAIL

"Express Mail" mailing label number: EV 600561554 US

Date of Deposit: February 7, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Hacey Stampy

Date

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(b)(3)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Attached is a list of documents on form PTO/SB/08A together with copies of each identified document. It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 CFR § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicants are in no way making any admission as to prior art status of the listed documents, but are instead submitting the listed documents for the sake of full disclosure under 37 CFR § 1.56.

Appl. No. 10/774,043 IDS dated February 7, 2006

To the best of the undersigned person's knowledge, this Information Disclosure Statement is being submitted in accordance with 37 CFR § 1.97(b)(3), before the mailing of a first Office action on merits.

It is believed that neither an extension of time, nor payment of any fee is required in connection with this communication. However, if an extension of time and corresponding extension fee, or any other fee is required, such an extension of time is hereby petitioned for and the Commissioner is authorized to charge any fees, or credit any overpayment, to Deposit Account No. 50-1627.

Respectfully submitted,

lintrew Lell

Andrew Gibbs

Registration No. 52,943

Intellectual Property Department Myriad Genetics, Inc. (Customer No. 26698) 320 Wakara Way Salt Lake City, UT 84108 Telephone:

801-584-3600

Fax:

801-883-3871

Date: February 7, 2006

PTO/\$B/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Seduction Act 25, no persons are required to respond to a collection of information unless is contains a valid OMB number.

CATRAS Complete if Known Substitute for form 1449A/PTO 10/774,043 **Application Number** INFORMATION DISCLOSURE Filing Date February 5, 2004 STATEMENT BY APPLICANT Qaber et al. First Named Inventor 1617 Art Unit Unknown **Examiner Name** (use as many sheets as necessary) Sheet 1 5808.04 Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1						
		BENVEGNU et al., "Diels-Alder Reactions on Linear Polyenes, Selectively Protected as their Tricarbonyl-Iron Complexes", Tetrahedron Letters, 1990, 31(22): 3145-3148					
		FRESHT, "Enzyme Structure and Mechanism", MRC Laboratory of Molecular Biology, WH Freeman& CO., 1977, pps: 18-28 and 302-324.					
		KRISHNAN et al., "Structure of thrombin complexed with selective non-electrophillic inhibitors having cyclohexyl moieties at P1", Acta Crystallographica, 2000, D56:294-303.					
		MATHEW et al., "Asymmetric synthesis and conformational analysis of the two enantiomers of the saturated analog of the potent thrombin inhibitorMOL-376", Tetrahedron Letters, 2002, volume date 2003, 44(3):583-586.					
		OH et al., Tryptase Inhibition Blocks Airway Inflammation in a Mouse Asthma Model", The Journal of Immunology, 2002, 168(4):1992-2000.					
		STORER et al., "Recent insights into cysteine protease specificity: Lessons for drug design", Perspectives in Drug Discovery and Design, 1996, 6:33-46.					
		THOMPSON et al., Section VI. Topics in Drug Design and Discovery, Chapter 24. Pharmacokinetics and Design of Aspartyl Protease Inhibitors, Annual Reports in Medicinal Chemistry, 2001, 36:247-256.					
	ļ						
	 						
	ļ						
	<u> </u>						
	├						
	\vdash						
Evaminer		Date					

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.